<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01292083</url>
  </required_header>
  <id_info>
    <org_study_id>1B-09-15</org_study_id>
    <secondary_id>NCI-2011-00117</secondary_id>
    <nct_id>NCT01292083</nct_id>
  </id_info>
  <brief_title>Azacitidine in Treating Patients With Triple Negative Stage I-IV Invasive Breast Cancer That Can Be Removed By Surgery</brief_title>
  <official_title>A Pilot Clinical Trial to Evaluate the Biological Activity of 5-azacitidine on ER and PR Expression in Triple Negative Invasive Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial studies azacitidine in treating patients with triple negative stage I-IV&#xD;
      invasive breast cancer that can be removed by surgery. Drugs used in chemotherapy, such as&#xD;
      azacitidine, work in different ways to stop the growth of tumor cells, either by killing the&#xD;
      cells or by stopping them from dividing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES: I. To evaluate the ability of deoxyribonucleic acid (DNA) methylation&#xD;
      inhibition using 5-azacitidine to induce expression of the estrogen receptor (ER) and&#xD;
      progesterone receptor (PR) genes in solid human triple negative invasive breast cancer.&#xD;
      SECONDARY OBJECTIVES: I. To determine the effect of systemic 5-azacitidine therapy on the&#xD;
      expression of other methylated genes in triple negative invasive breast cancer using an&#xD;
      Illumina GoldenGate array. OUTLINE: Patients receive azacitidine intravenously (IV) over&#xD;
      10-40 minutes 5 days a week for 2 weeks in the absence of disease progression or unacceptable&#xD;
      toxicity. Patients undergo definitive breast surgery within 12 days of the last dose of&#xD;
      azacitidine.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No accrual last 2 years&#xD;
  </why_stopped>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of participants with ER/PR response after receiving 10 doses of 5-Azacitidine</measure>
    <time_frame>6 months after enrollment of last patient</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IA Breast Cancer</condition>
  <condition>Stage IB Breast Cancer</condition>
  <condition>Stage II Breast Cancer</condition>
  <condition>Stage IIIA Breast Cancer</condition>
  <condition>Stage IIIB Breast Cancer</condition>
  <condition>Stage IIIC Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>See Detailed Description</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>azacitidine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>5-AC</other_name>
    <other_name>5-azacytidine</other_name>
    <other_name>azacytidine</other_name>
    <other_name>Vidaza</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>immunohistochemistry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>PCR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>western blotting</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Blotting, Western</other_name>
    <other_name>Western Blot</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>nucleic acid sequencing</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Gene Sequencing</other_name>
    <other_name>Molecular Biology, Nucleic Acid Sequencing</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
    <description>Undergo definitive breast surgery</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Resectable tumor measuring 2 cm or more&#xD;
&#xD;
          -  Histologically documented triple negative invasive breast cancer characterized by 0%&#xD;
             Immunohistochemistry (IHC) nuclear staining for ER-alpha, 0% IHC nuclear staining for&#xD;
             PR-alpha, and no amplification of HER2/neu by fluorescence in situ hybridization&#xD;
             (FISH); standard IHC assays for ER and PR use antibodies to ER-alpha and PR-alpha and&#xD;
             PR-beta&#xD;
&#xD;
          -  Southwest Oncology Group (SWOG) performance status of less than or equal to 1&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt;= 1500/Î¼L&#xD;
&#xD;
          -  Hemoglobin (Hgb) &gt;= 9 g/dL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/uL&#xD;
&#xD;
          -  Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) and&#xD;
             alanine aminotransferase (ALT)/serum glutamic pyruvate transaminase (SGPT) =&lt; 2.5 x&#xD;
             upper limit normal (ULN) or =&lt; 5.0 x ULN in patients with liver metastases&#xD;
&#xD;
          -  Creatinine =&lt; 2.0 mg/dL Or Calculated Creatinine Clearance &gt;= 50 ml/min&#xD;
&#xD;
          -  Albumin &gt;= 3 g/dL&#xD;
&#xD;
          -  Potassium &gt;= lower limit normal (LLN)&#xD;
&#xD;
          -  Phosphorous &gt;= LLN&#xD;
&#xD;
          -  Calcium &gt;= LLN&#xD;
&#xD;
          -  Magnesium &gt; LLN&#xD;
&#xD;
          -  Women of childbearing potential must have a negative serum or urine pregnancy test&#xD;
             performed within 7 days prior to start of treatment&#xD;
&#xD;
          -  Accessible for treatment and follow-up&#xD;
&#xD;
          -  Written informed consent prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HER2/neu amplification by FISH&#xD;
&#xD;
          -  Concurrent neoadjuvant treatment with chemotherapy, endocrine therapy, or radiotherapy&#xD;
&#xD;
          -  Known hypersensitivity to azacitidine or mannitol&#xD;
&#xD;
          -  Preexisting hepatic impairment or renal impairment&#xD;
&#xD;
          -  Intent to receive additional neoadjuvant therapy prior to surgery&#xD;
&#xD;
          -  Concurrent use of an histone deacetylase (HDAC) inhibitor or hydralazine&#xD;
&#xD;
          -  Known diagnosis of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
          -  Major surgery &lt; 4 weeks prior to starting study drug&#xD;
&#xD;
          -  Pregnant or breastfeeding or female of reproductive potential not using an effective&#xD;
             method of birth control&#xD;
&#xD;
          -  Other concurrent severe, uncontrolled infection or intercurrent illness, including but&#xD;
             not limited to ongoing or active infection or psychiatric illness/social situations&#xD;
             that would limit compliance with study requirements&#xD;
&#xD;
          -  Prior antiestrogens (selective estrogen receptor modulator [SERM] or aromatase&#xD;
             inhibitors) within 6 months of study entry&#xD;
&#xD;
          -  Underlying medical, psychiatric or social conditions that would preclude patient from&#xD;
             receiving treatment&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agustin Garcia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>February 2, 2011</study_first_submitted>
  <study_first_submitted_qc>February 7, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2011</study_first_posted>
  <last_update_submitted>February 5, 2014</last_update_submitted>
  <last_update_submitted_qc>February 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 6, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

